Prophylactic or therapeutic agent for retinal diseases and method for preventing or treating retinal diseases, each comprising jnk (c-jun n-terminal kinase)-inhibiting peptide, and use of the peptide

A technology for retinal diseases and preventive agents, applied in the field of preventing or treating retinal diseases, and preparing preventive or therapeutic agents for retinal diseases

Inactive Publication Date: 2012-02-29
SANTEN PHARMA CO LTD
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, there are no reports showing that JNK inhibitors other than SP600125 are effective for the treatment or prevention of retinal diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prophylactic or therapeutic agent for retinal diseases and method for preventing or treating retinal diseases, each comprising jnk (c-jun n-terminal kinase)-inhibiting peptide, and use of the peptide
  • Prophylactic or therapeutic agent for retinal diseases and method for preventing or treating retinal diseases, each comprising jnk (c-jun n-terminal kinase)-inhibiting peptide, and use of the peptide
  • Prophylactic or therapeutic agent for retinal diseases and method for preventing or treating retinal diseases, each comprising jnk (c-jun n-terminal kinase)-inhibiting peptide, and use of the peptide

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0137] (Preparation Example 1: Injection)

[0138] In 10mL:

[0139] A peptide 10mg

[0140] Sodium chloride 90mg

[0141] Appropriate amount of polysorbate 80

[0142] Appropriate amount of sterile purified water

[0143] Peptide A and other components listed above are dissolved in sterile purified water to prepare injections. Injections containing 0.1 mg, 1 mg or 50 mg of A peptide in 10 ml can be prepared by changing the amount of A peptide added.

preparation Embodiment 2

[0144] (Formulation Example 2: Eye Drops (0.01% (w / v)))

[0145] In 100ml:

[0146]

[0147]

[0148] Peptide A and other ingredients listed above are added to sterile purified water and mixed well to prepare an ophthalmic solution. Drops containing peptide A at concentrations of 0.05% (w / v), 0.1% (w / v), 0.5% (w / v), or 1% (w / v) can be prepared by varying the amount of peptide A added eye drops.

preparation Embodiment 3

[0149] (Formulation Example 3: tablet)

[0150] In 100mg:

[0151]

[0152] Peptide A and lactose are mixed in a mixer. Carboxymethylcellulose calcium and hydroxypropylcellulose were added to the mixture, and the mixture was granulated. The resulting granules were dried and sized, magnesium stearate was added to the sized sized granules and blended, after which the mixture was compressed into tablets in a tablet machine. By changing the amount of peptide A added, tablets containing 0.1 mg, 10 mg or 50 mg of peptide A in 100 mg can be prepared.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The intravitreal administration of a JNK-inhibiting peptide which comprises (a) at least either one of the JNK-inhibiting sequences depicted in SEQ ID NO:1 and SEQ ID NO:2 and (b) at least either one of the transfer sequences depicted in SEQ ID NO:3 and SEQ ID NO:4 and has a length shorter than 150 amino acid residues wherein at least one amino acid residue is a D-amino acid residue can prevent the occurrence of spermidine-induced damage of retinal pigment epitheliums, tunicamycin-induced visual cell injury, and laser-induced choroidal neovascularization. Therefore, the JNK-inhibiting peptide is useful for the prevention or treatment of retinal diseases. By using the JNK-inhibiting peptide, it becomes possible to provide a medicinal agent and a method both of which can prevent or treat retinal diseases through topical administration in eyes. It also becomes possible to provide use of the JNK-inhibiting peptide for the production of the medicinal agent.

Description

technical field [0001] The present invention relates to a preventive or therapeutic agent for retinal diseases, the preventive or therapeutic agent comprising a JNK inhibitory peptide as an active ingredient, the JNK inhibitory peptide comprising a specific amino acid sequence, the length of which is less than 150 amino acids, and comprising At least one D-amino acid. The present invention also relates to methods of preventing or treating retinal diseases using such JNK inhibitory peptides. Furthermore, the present invention relates to the use of such a JNK inhibitory peptide for the preparation of a preventive or therapeutic agent for retinal diseases. Background technique [0002] Retinal diseases are members of the most important family of diseases in the field of ophthalmology. Many retinal diseases are difficult to treat, and severe symptoms that can cause blindness occur frequently. Representative examples of retinal diseases include age-related macular degeneration...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61P27/02A61P43/00C07K7/06C07K7/08C07K14/00C12N9/99
CPCA61K38/04C07K7/06C07K7/08C07K2319/00A61P27/02A61P43/00A61P9/10A61K38/10A61K38/08A61K9/0048
Inventor 平井慎一郎松下登起义藤田由纪惠仓岛宏明大桥康司
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap